Signpath Pharma

Signpath Pharma is a private, clinical-stage biotech leveraging its patented CorreQT platform to develop cardiac-safe drugs. Its primary focus is mitigating the cardiotoxicity associated with chemotherapies and other drug classes. The company's most advanced asset, LipoCurc™, has completed Phase 1 trials and is now in a Phase 2 study for glioblastoma, while its platform technology is being applied to create new compounds like SPP4040. With leadership experienced in biotech and cardiology, Signpath is targeting significant unmet needs in oncology supportive care and broader drug safety.

Patented CorreQT platform designed to mitigate cardiac side effects (arrhythmia, muscle damage) of other drugs through reformulation or co-administration, enabling the creation of cardiac-safe versions across multiple drug classes.

Competition includes generic cardioprotectants like dexrazoxane and companies developing novel formulations of existing chemotherapies. Signpath's differentiation lies in its broad platform approach targeting multiple mechanisms of cardiotoxicity and its lead immuno-oncology asset, LipoCurc™.